Log in to search using one of your social media accounts:


Drugs in Clinical Development for Fungal Infections (includes MAT023, encochleated amphotericin B))

Despite increasing rates of invasive fungal infections being reported globally, only a single antifungal drug has been approved during the last decade. Resistance, toxicity, drug interactions and restricted routes of administration remain unresolved issues. This review focuses on new antifungal compounds which are currently in various clinical phases of development. We discuss two azoles with a tetrazole moiety that allows selective activity against the fungal CYP: VT-1161 for Candida infections and VT-1129 for cryptococcal meningoencephalitis.
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news

Related Links:

More News: Abelcet | Aspergillus | Candida | Fungal Infections | Men | Respiratory Medicine | Toxicology | Websites